Enveric Biosciences (NASDAQ:ENVB – Get Free Report) and MediciNova (NASDAQ:MNOV – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.
Profitability
This table compares Enveric Biosciences and MediciNova’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Enveric Biosciences | N/A | -220.97% | -177.47% |
| MediciNova | -1,962.98% | -27.28% | -25.24% |
Valuation & Earnings
This table compares Enveric Biosciences and MediciNova”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Enveric Biosciences | N/A | N/A | -$8.77 million | ($23.54) | -0.07 |
| MediciNova | $410,000.00 | 152.46 | -$12.00 million | ($0.23) | -5.52 |
Enveric Biosciences has higher earnings, but lower revenue than MediciNova. MediciNova is trading at a lower price-to-earnings ratio than Enveric Biosciences, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of recent ratings and target prices for Enveric Biosciences and MediciNova, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Enveric Biosciences | 1 | 0 | 0 | 0 | 1.00 |
| MediciNova | 1 | 1 | 3 | 2 | 2.86 |
MediciNova has a consensus target price of $7.50, suggesting a potential upside of 490.55%. Given MediciNova’s stronger consensus rating and higher possible upside, analysts plainly believe MediciNova is more favorable than Enveric Biosciences.
Insider and Institutional Ownership
13.8% of Enveric Biosciences shares are owned by institutional investors. Comparatively, 9.9% of MediciNova shares are owned by institutional investors. 2.4% of Enveric Biosciences shares are owned by insiders. Comparatively, 14.0% of MediciNova shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Volatility and Risk
Enveric Biosciences has a beta of 1.11, suggesting that its share price is 11% more volatile than the S&P 500. Comparatively, MediciNova has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500.
Summary
MediciNova beats Enveric Biosciences on 9 of the 14 factors compared between the two stocks.
About Enveric Biosciences
Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.
About MediciNova
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.
Receive News & Ratings for Enveric Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enveric Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
